Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
998 studies found for:    "Macular Degeneration"
Show Display Options
Rank Status Study
21 Completed Palomid 529 in Patients With Neovascular Age-Related Macular Degeneration
Condition: Age-Related Macular Degeneration
Intervention: Drug: Palomid 529
22 Terminated 12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: pazopanib eye drops
23 Completed
Has Results
Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Macugen
24 Completed Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: AdGVPEDF.11D
25 Completed Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
Condition: Macular Degeneration
Interventions: Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL;   Drug: Anecortave Acetate Sterile Suspension, 60 mg/mL;   Other: Anecortave Acetate Vehicle
26 Active, not recruiting Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
Conditions: Macular Degeneration;   Age-Related Maculopathies;   Age-Related Maculopathy;   Maculopathies, Age-Related;   Maculopathy, Age-Related;   Retinal Degeneration;   Retinal Neovascularization;   Gene Therapy;   Therapy, Gene;   Eye Diseases
Intervention: Biological: AAV2-sFLT01
27 Completed A Study to Evaluate Pazopanib Tablets in Patients Who Have Neovascular Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: Pazopanib
28 Recruiting Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Interventions: Drug: Regorafenib, ophthalmic oily suspension (BAY73-4506);   Procedure: Sham IVT;   Drug: Ranibizumab;   Drug: Placebo
29 Completed Celecoxib to Treat Macular Degeneration in Patients Receiving Photodynamic Therapy
Condition: Macular Degeneration
Intervention: Drug: Celecoxib
30 Completed Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)
Condition: Macular Degeneration
Intervention: Drug: rhuFab V2 (ranibizumab)
31 Completed Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration
Condition: Wet Macular Degeneration
Interventions: Drug: Ketorolac + Ranibizumab;   Drug: Ranibizumab
32 Completed Neovascular Age Related Macular Degeneration (AMD), Periocular Corticosteroids, and Photodynamic Therapy (PDT)
Conditions: Choroidal Neovascularization;   Age-Related Macular Degeneration
Intervention: Drug: Periocular injection of triamcinolone acetonide 40mg
33 Recruiting Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration
Condition: Wet Macular Degeneration
Intervention: Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
34 Unknown  Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
Condition: Age-related Macular Degeneration
Intervention: Drug: Pegaptanib (Macugen®)
35 Completed Identification and Treatment of Feeder Vessels in Macular Degeneration
Condition: Macular Degeneration
Interventions: Procedure: Angiography;   Procedure: Laser Treatment
36 Not yet recruiting X-82 to Treat Age-related Macular Degeneration
Conditions: Age-Related Macular Degeneration (AMD);   Macular Degeneration;   Exudative Age-related Macular Degeneration;   AMD;   Macular Degeneration, Age-related, 10;   Eye Diseases;   Retinal Degeneration;   Retinal Diseases
Interventions: Drug: X-82;   Drug: Aflibercept
37 Recruiting Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration
Conditions: Exudative Macular Degeneration;   Retinal Hemorrhage
Interventions: Drug: Ranibizumab;   Drug: C3F8 Gas;   Drug: tPA
38 Withdrawn Combination Therapy for Neovascular Age Related Macular Degeneration
Condition: Macular Degeneration
Intervention: Drug: intravitreal bevacizumab and triamcinolone acetonide
39 Recruiting Neovascular Age-related Macular Degeneration
Condition: Neovascular Age-related Macular Degeneration
Intervention:
40 Recruiting Complement Factor H Haplotypes and Smoking in Age-related Macular Degeneration
Condition: Macular Degeneration
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years